SGC-CBP30

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

SGC-CBP30 是一种有效的 CREBBP/EP300 抑制剂 (IC50: 21/38 nM)。

SGC-CBP30 is a potent and selective inhibitor of CREBBP (CBP) and EP300; which are general transcriptional co-activators. CREBBP has also been associated with Amyotrophic Lateral Sclerosis (ALS) or Lou Gehrig?’s disease, a neurodegenerative disease with progressive degeneration of motor neurons in the brain and spinal cord, Alzheimer's disease and poly glutamine repeat diseases such as Spinal and Bulbar Muscular Atrophy and Huntington?’s disease.

——

Animal Model:Sprague-Dawley (SD) rats (aged 3-4 weeks) injected with NSC-125066 Dosage:25 mg/kg Administration:Oral administration; daily; for 14 days Result:Slightly alleviated alveolar bronchial fibrosis induced by NSC-125066.

SGC-CBP30 | SGC-CBP 30 | SGC-CBP-30

Others

Other Targets

CREBBP| EP300

Cancer

——

1613695-14-9

509.04

C28H33CIN4O3

>98% (HPLC)

DMSO : ≥ 31 mg/mL; 60.90 mM

Cc1noc(C)c1c1cc2nc(CCc3ccc(OC)c(Cl)c3)n(C[C@H](C)N3CCOCC3)c2cc1

(S)-4-(1-(2-(3-chloro-4-methoxyphenethyl)-5-(3,5-dimethylisoxazol-4-yl)-1H-benzo[d]imidazol-1-yl)propan-2-yl)morpholine

(-20℃)

With Ice Pack

≥ 2 years